Objective: To identify evidence of the impact of Haemophilus influenzae type b (Hib) conjugate vaccine on the epidemiology of invasive Hib disease.
Introduction
Haemophilus influenzae is a gram-negative bacterium that may, depending on the chemical structure of the external polysaccharide layer, be capsulated or nonencapsulated. In the latter case, it is also called nontypable. Of the six capsulated types of H. influenzae (a, b, c, d, e, f), type b (Hib) is the main cause of invasive disease in childhood, especially in non-industrialized regions, including meningitis, epiglottitis, septicemias, osteomyelitis, arthritis and non-invasive diseases such as pneumonia and otitis. Although there is a highly effective vaccine available, at the beginning of the 21st century Hib still represents an important cause of morbidity and mortality in childhood in developing countries, especially where the Hib vaccine has not yet been introduced. 1 Technology capable of conjugating a protein derivative to capsular polysaccharide has culminated in the production of a vaccine able to stimulate the immunologic system with a T-dependent response, for use in children under the age of 2 years. The efficacy and safety of conjugate Hib vaccines has been proved by several investigations, even when associated or combined with other vaccines. 2, 3 However, knowledge of the efficacy and safety of these vaccines is not enough for their large-scale implementation.
In developing regions, the cost-effectiveness of vaccination becomes the main aspect in the decision to introduce the vaccine in public health. [4] [5] [6] [7] In addition, the scarcity of local data on the incidence of Hib, the high cost of the vaccine and the lack of knowledge about the effectiveness of vaccination in populations with different epidemiologic and genetic characteristics than those of developed countries, has limited the incorporation of the vaccine in immunization programs in developing countries. From this standpoint, studies on the burden of disease to be prevented are paramount for supporting control programs. [8] [9] [10] The worldwide burden of H. influenzae b
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annually all over the world. 1 In several world regions, the relevance of Hib as a cause of invasive infections in childhood are well documented, thus justifying the costeffectiveness of vaccination in these countries. 7 In Gambia, Hib incidence rates of 60 x 10 5 were detected at the end of the 1980s. 12 More recently, countries like Ghana (72 x 10 5 ) and Uganda (59 x 10 5 ) presented the highest rate of meningitis due to Hib in a World Health Organization (WHO) assessment in 11 African countries. 13 Austria. 1, 12, 14 On the other hand, in Asia, conflicting and sometimes inconclusive results about the incidence of meningitis [15] [16] [17] have made it difficult to obtain reliable evidence to support control programs, thus retarding the introduction of Hib vaccine on that continent. However, in countries like Bangladesh, surveillance data have proven that Hib is the main cause of meningitis in childhood. 18 The recently published results of the field trial in Lombok, Indonesia, generated astounding information, showing not only the high incidence of meningitis due to Hib in the region (134 x 100,000), but also a high incidence of meningitis prevented by Hib vaccine under routine immunization conditions. 19 In Latin America, Chile was the first country to show the cost-effectiveness of the Hib vaccine in preventing Hib invasive disease. 20 In Brazil, Hib vaccination was introduced in mid-1999. The scarce publications that measured the role of Hib as etiologic agent of meningitis in children before the introduction of conjugate vaccines showed coefficients close to those found in European countries in the 1990s. The risk for meningitis due to Hib in the prevaccination period in Brazil ranged from 10.8 to 17 per 100,000 children. 21, 22 Effectiveness of vaccination against Hib Invasive Hib disease has practically disappeared in the industrialized countries in which the conjugate vaccine has been used for over 15 years in routine immunization programs. [26] [27] [28] [29] [30] Similarly, the vaccination produced great impact in developing countries, with significant decline especially of meningitis due to Hib. 7, 31, 32 In several industrialized regions, the availability of efficient surveillance systems with reliable epidemiological baseline made it feasible to monitor Hib meningitis under programmatic conditions. Thus, the majority of studies about the effectiveness of vaccination come from the USA and Europe. Surveillance data in these countries have detected a decline higher than 80% in Hib meningitis soon after the vaccine was introduced. 14, 26, 29, 33 In Latin America, the vaccination impact on meningitis was assessed in Cuba, Colombia, Uruguay, Chile and Brazil, 31 showing a 40 to 95% decline in the incidence rates of Hib meningitis in the post-vaccination period, compared with the pre-vaccination period, as shown in Table 1 [1990] [1991] [1992] [1993] . 32 In Asia, in the probe trial conducted in Lombok, vaccination was introduced in the health services in a randomized fashion, with DPT vaccination as a comparison group, and the results showed a considerable decline in the incidence of meningitis preventable by vaccination against Hib, which ranged from 67 to 158 per 100,000 children-year. 19 In pneumonia, vaccination effectiveness was initially shown in the field trial conducted in Gambia in Africa, where the vaccine reduced pneumonia cases with alveolar consolidation by 22.4% in the vaccinated group compared with the control group. 23 A similar result was observed in
Chile after the vaccine was introduced in the health services, where a 22% reduction in pneumonia was observed, assessed by a retrospective study of hospital charts. 24 More recently, three case-control studies were conducted, two in South America and one in Asia. In Brazil, the investigation was designed to be part of the structure of a population-based prospective surveillance system to detect radiologically diagnosed cases of pneumonia. Under programmatic conditions, vaccination against Hib reduced the incidence of pneumonia by 31% in Brazil, by 55% in Colombia and by 45% in Bangladesh. [43] [44] [45] In the current state of the art there is well established evidence of the causal relationship between vaccination against Hib and reduction in mortality by pneumonia in children under 5 years of age in developing countries. 46, 47 However, there is still scarce information on the effect of Hib vaccination on mortality due to invasive diseases worldwide. Recent surveillance data from central Brazil showed that the mortality rate due to bacterial invasive disease in children from 2 to 23 months old fell from 72.8% to 49.0% per 100,000 children-year of observation, in the second year after Hib vaccine was introduced. 48 The greatest reduction was observed in mortality by bacterial meningitis (12.8 to 3.5/100,000), followed by reduction in radiologically confirmed pneumonia (36.5 to 24.5/ 100,000).
Reappearance of invasive Hib disease cases
The United Kingdom (UK) is among the countries in which a marked reduction was documented in the number of cases of invasive infections caused by Hib after the conjugate Hib vaccine was included in the routine vaccination program for infants in 1992. 29 However, in that country, a growing number of cases of severe infection due to Hib began to be observed from 1998 onwards, in children born as of 1996. 49 The number of cases among children under the age of 5 years was over 800 per year before the vaccine had been implemented, whereas in 2002 there were 134 cases registered in the same age group, and 266 in all age groups. 50 In addition to the use of a basic vaccination scheme in the first year of life (1 dose The mass campaign strategy for children aged from 1 to 4 years probably accelerated the drop in the frequency of invasive Hib disease cases in the UK, as it caused a rapid reduction in the number of susceptible individuals (< 5 years). Nonetheless, in The Netherlands, where the above strategy was not used, the speed of reduction of the frequency of invasive Hib disease was much lower. 51 But the increased incidence of meningitis and epiglottitis due to Hib in 2002 was described in The Netherlands in a similar manner as it occurred in the UK. 52 Therefore, it is unlikely that the increased incidence of cases in the UK had been due to chance.
The number of invasive Hib disease cases in the UK has doubled every year, as of 1998, and the great majority of cases occurred in inadequately vaccinated children. 50 Several factors have been identified as being responsible In addition to the reduction in cases among immunized children, a reduction has been documented in invasive
Hib disease in non-immunized individuals of an age equal to or older than 15 years. 56 The indirect protection established in this age group may be attributed to the so called herd immunity, in which the effect is extended to groups of a community, in addition to the groups in which the preventive action was implemented. This herd immunity may be attributed to the reduced circulation of Hib in the community. However, a rise in the number of infections by Hib among adults has also been documented in the UK as of 1998, reaching pre-vaccination levels in
2003. 57 In a study in which the antibody levels for Hib among English adults were measured, significant reduction was described in 1994, in comparison with the antibody levels measured in 1991 in the same age group (p = 0.006). 57 In another study, the antibody level for lower than the titers of the same age group whose samples were collected in 1994. 54 Therefore, in the absence of a booster stimulus, the antibodies for Hib induced by vaccination during the first year of life tend to progressively diminish during the period from 2 to 3 years. 54 The titer levels of Hib antibodies with protective effect in the short and longterm were previously determined (0.15-1.0 mg/L). 58 It is possible that the increase in the number of invasive Hib disease cases is secondary to a lesser protection than it was expected. 59 The reduction in Hib circulation in the community led to the loss of the natural booster stimulus that existed when the immunized child was colonized by
Hib. Thus, the reduction in this circulation, which resulted from the initial use of the vaccine in the 1990s, 60 
